Soybean Oil, Mct, Olive Oil And Fish Oil Intravenous Lipid Emulsion Suppliers & Bulk Manufacturers
Available Forms: Infusion
Available Strengths: 100 mL, 250 mL, 500 mL, 1000 mL
Reference Brands: SMOF lipid (UK)
Category:
Parenteral Nutrition
soybean oil, MCT, olive oil and fish oil intravenous lipid emulsion is available in Infusion
and strengths such as 100 mL, 250 mL, 500 mL, 1000 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, soybean oil, MCT, olive oil and fish oil intravenous lipid emulsion is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
soybean oil, MCT, olive oil and fish oil intravenous lipid emulsion can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
SMOFlipid is a multi-component intravenous lipid emulsion composed of soybean oil, medium-chain triglycerides (MCT), olive oil, and fish oil. It is increasingly used in neonatal intensive care units as part of parenteral nutrition for very preterm infants. Designed to provide a balanced fatty acid profile, SMOFlipid aims to support growth while potentially reducing inflammation-related complications compared to traditional soybean-based lipid emulsions such as intralipid.
Clinical evaluations comparing SMOFlipid with soybean-based lipid emulsions have shown mixed outcomes. In very preterm infants, SMOFlipid has been associated with lower growth velocity between birth and 36 weeks of corrected gestational age, particularly among male infants. At the same time, it has demonstrated a reduced incidence of bronchopulmonary dysplasia (BPD), suggesting possible pulmonary protective effects. However, some data also indicate a higher rate of late-onset sepsis in infants receiving SMOFlipid.
These findings highlight that SMOFlipid may offer certain clinical advantages while presenting potential risks, making it a balanced yet complex option in neonatal nutritional management. Careful patient selection and further research are essential to better define its long-term safety and efficacy in very preterm populations.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing